Head of EU pharma trade body says waiver would ‘open the door to counterfeit vaccines’ and kill incentives to tackle dangerous virus variants. ‘Who will make the vaccine next time?’ one pharma chief asks
As COVID-19 shows, older people are particularly vulnerable to infectious diseases. IMI’s VITAL project is studying vaccines and immunity in older adults, to figure out the best strategies to keep people healthier for longer.
As the problem of COVID-19 vaccines supplies so potently illustrates, it is time to rethink the EU’s pandemic preparedness strategy. More support is needed for late stage clinical development and large scale manufacturing